Blood Pressure Variability and Cardiovascular Disease Events in Patients With Hypertension (BPV)

April 14, 2020 updated by: Professor Chia Yook Chin, University of Malaya

Relationship of Blood Pressure Variability and Cardiovascular Disease Events Among Patients With Hypertension

Cardiovascular Disease (CV) including stroke is the leading cause of death in Malaysia Hypertension is a major contributor to this. Prevalence of hypertension in Malaysia is high (42%) in adults age 30 years or older. Besides the actual blood pressure (BP) level recently, blood pressure variability (BPV) has been recognized as an independent and strong predictor of CV events especially strokes. However, data on the BP variability and its relationship to CV events is very limited in Asia, particularly in Malaysia. Hence the investigators aim to study BPV and its relationship to CV events in treated hypertensive patients

Study Overview

Detailed Description

This will be a cross-sectional study on patients with hypertension. The 10-year retrospective data on BP, treatment, biochemical changes, kidney function and CV events will be extracted from patient records.

Eligible patients who have given written informed consent will be given a questionnaire capturing data of their socio-demographic status, weight, height and BP measured.

Those agreeable to measure their own BP at home 3 times a day for a week will be loaned a BP device to measure their own BP at home. The home BP readings will be recorded onto a provided form and returned to the investigators.

Data will be analysed to

  1. determine BPV of the clinic visit-to-visit BPV (long tem BPV)
  2. determine the day to day BPV (short term BPV)
  3. examine the BPV to CV events, kidney function, cognition
  4. determine the prevalence of white coat and masked hypertension
  5. determine the level of control of BP
  6. examine the relationship of ownership of home BP devices to control and satisfaction of treatment

Study Type

Observational

Enrollment (Actual)

1736

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

    • Federal Territory
      • Kuala Lumpur, Federal Territory, Malaysia, 59100
        • University of Malaya Medical Centre

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

18 years and older (ADULT, OLDER_ADULT)

Accepts Healthy Volunteers

No

Genders Eligible for Study

All

Sampling Method

Non-Probability Sample

Study Population

All adult patients with hypertension on follow up at the primary care clinic of University of Malaya Medical Centre who fulfill the inclusion and exclusion criteria are eligible to be enrolled into the study

Eligible patients were recruited in a consecutive manner

Description

Inclusion Criteria:

  • Patients on treatment for hypertension of at least 3 years
  • Patients who consent to the study

Exclusion Criteria:

  • those unable to give consent
  • recent (less than 6 months) of cardiovascular events (stroke, heart attack, heart failure)
  • patients on dialysis
  • patients with end stage kidney failure

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
The standard deviation value of blood pressure variability in treated hypertensive patients
Time Frame: 31 Dec 2020
The various indices of day-to-day and long term Blood pressure variability will be calculated giving the actual BPV (in absolute number ) in these patients
31 Dec 2020
Percentage of cardiovascular events in those with higher BPV compared to those with lower BPV
Time Frame: 31 Dec 2020
BPV will be categorized as above or below the mean BPV of the entire group. The number of CV events in percentage in each group will be compared It is expected that those with higher BPV will have more CV events
31 Dec 2020

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Percentage of Treated hypertensives with White Coat or Masked hypertension
Time Frame: 31 Dec 2020
The Home and Clinic BP measurements will be used to determine the percentage of Masked and White Coat Hypertension. These two conditions are expected to be associated with more CV events than those with control of both clinic and home BP.
31 Dec 2020
Difference in cognition in those with higher BP variability compared to those with lower BPV
Time Frame: 31 Dec 2020
The Montreal Cognitive Assessment (MoCA) score will be compared between those with higher with those with lower BPV. The minimum MoCA score is 0 and the maximum is 30. A higher MoCA score indicates better cognition. A MoCA score of 26 is considered as normal. The MoCA score is expected to be lower in those with higher BPV.
31 Dec 2020

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Investigators

  • Study Director: Lai M Looi, MBBS FRCPath, University of Malaya Medical Centre

Publications and helpful links

The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.

General Publications

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (ACTUAL)

July 14, 2017

Primary Completion (ACTUAL)

July 4, 2019

Study Completion (ACTUAL)

December 31, 2019

Study Registration Dates

First Submitted

April 8, 2020

First Submitted That Met QC Criteria

April 10, 2020

First Posted (ACTUAL)

April 13, 2020

Study Record Updates

Last Update Posted (ACTUAL)

April 16, 2020

Last Update Submitted That Met QC Criteria

April 14, 2020

Last Verified

April 1, 2020

More Information

Terms related to this study

Additional Relevant MeSH Terms

Other Study ID Numbers

  • 2017314-5047
  • WI207736 (OTHER_GRANT: Pfizer)

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

NO

IPD Plan Description

The data are only useful for this study

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Cardiovascular Diseases

Clinical Trials on non-interventional

Subscribe